ONPH - Oncology Pharma Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0284
+0.0124 (+77.50%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.0160
Open0.0170
BidN/A x N/A
AskN/A x N/A
Day's Range0.0150 - 0.0284
52 Week Range0.0050 - 0.0600
Volume522,178
Avg. Volume184,743
Market Cap3.306M
Beta (3Y Monthly)-2.01
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire

    Update: Oncology Pharma Signed a Letter of Intent with Kalos Therapeutics for an Exclusive World-Wide License and Co-Development of Its Broad-Spectrum Anti-Cancer Drug, KTH 222

    SAN FRANCISCO, CA, Aug. 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Oncology Pharma (OTCPK: ONPH)is pleased to announce that it signed a Letter of Intent with Kalos Therapeutics (Phoenix, AZ) for a world-wide license and co-development of Kalos's lead anti-cancer drug, KTH 222. The expected license and co-development of KTH 222 as a monotherapy and/or in combination with NanoSmart's ANA-conjugated liposomal doxorubicin targeted delivery is licensed exclusively worldwide by Oncology Pharma. Doxorubicin is one of the most commonly used chemotherapies for treating a wide variety of cancers such as breast, ovarian, lung, bladder, lymphoma, and Kaposi's sarcoma.

  • GlobeNewswire

    Oncology Pharma Signed a Letter of Intent with Kalos Therapeutics for an Exclusive World-Wide Licence and Co-Devlopent of Its Broad-Spectrum Anti-Cancer Drug, KTH 222

    SAN FRANCISCO, CA, Aug. 19, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Oncology Pharma (OTCPK: ONPH) is pleased to announce that it signed a Letter of Intent with Kalos Therapeutics (Phoenix, AZ) for a world-wide license and co-development of Kalos's lead anti-cancer drug, KTH 222. The expected license and co-development of KTH 222 as a monotherapy and/or in combination with NanoSmart's ANA-conjugated liposomal doxorubicin targeted delivery is licensed exclusively world-wide by Oncology Pharma. Doxorubicin is one of the most commonly used chemotherapies for treating a wide variety of cancers such as breast, ovarian, lung, bladder, lymphoma, and Kaposi's sarcoma. Kalos Therapeutics is developing a platform of drugs containing multiple array of natriuretic peptide which have demonstrated a broad spectrum of anti-tumor activity with negligible or no known adverse effects.

  • GlobeNewswire

    Oncology Pharma Appoints Stefan Gruenwald (MD. Ph.D) as an Advisor on its Advisory Board

    SAN FRANCISCO, CA, July 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Oncology Pharma, Inc.  (OTCPK: ONPH) is pleased and honored to announce the appointment of Stefan Gruenwald (MD. Ph.D) to its Advisory Board.  Dr. S. Gruenwald brings more than 30 years of experience and vast knowledge in both the clinical, scientific and business fields to the company.  His contribution to meeting the vision, mission and goals are a great asset to the company. Dr. Gruenwald has had an impressive career as the former VP of R&D at Becton Dickenson, the former CSO at Pharmingen and the former President at Orbigen.

  • GlobeNewswire

    SourcingLink.net Announces Corporate Name Change to Oncology Pharma, Inc.

    SAN FRANCISCO, CA, June 17, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – SourcingLink.net, Inc. has announced that it has changed its name to ONCOLOGY PHARMA, INC. (OTCPK: ONPH) (the “Company”). In addition to the new corporate name, the Company has also changed it ticker symbol on the OTC Markets to “ONPH”. The new name was chosen to better reflect the Company’s strategic focus on the development, manufacture, and commercialization of oncology treatments and therapeutics.